Navigation Links
BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
Date:3/4/2008

BIRMINGHAM, Ala., March 4 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the fourth quarter and year ended December 31, 2007.

"In 2007, we gained greater clarity in terms of the progress made in each of our lead product programs, peramivir, forodesine HCl and BCX-4208," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "Each program is now either in mid-stage clinical testing or, in the case of forodesine HCl, a pivotal trial. Over the course of the year, we have assembled a strong management team to execute on our commitments and advance our product candidates in 2008."

Fourth Quarter 2007 Financial Results

The Company reported revenues of $28.2 million in the fourth quarter of 2007, compared to $2.1 million in the fourth quarter of 2006. The increase in revenues is due to revenue from the contract with the U.S. Department of Health and Human Services ("HHS") for the development of peramivir, a $7.0 million milestone payment received from Shionogi & Co., Ltd., and the continuing amortization of deferred revenue from our collaborative agreements.

The net loss for the quarter ended December 31, 2007 was $2.3 million, or $0.06 per share, compared to a net loss of $10.1 million, or $0.34 per share, for the quarter ended December 31, 2006.

Research and development ("R&D") expenses were $29.1 million in the fourth quarter of 2007, compared to $11.2 million in the fourth quarter of 2006. The increase in R&D expenses is primarily attributable to an increase in clinical trial related expenses, manufacturing costs for our lead product candidates and costs related to an increase in the personnel supporting the advanced development of our pro
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
2. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
5. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
6. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
8. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
9. Genetic Engineering & Biotechnology News reports on advances in miRNA
10. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
11. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015  Prima Biomed Ltd. (NASDAQ: PBMD ) ... become a leader in the development of immunotherapeutic products ... final CVac data from the Phase II CAN-003 ovarian ... a clinically meaningful improvement in Overall Survival ("OS") over ... In the group of second remission patients (n=20), ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... Worms, Germany (PRWEB) May 21, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACTâ„¢, an independent subsidiary of the International Pharmaceutical ... three Grace facilities that produce its SYLOID® FP ... now received GMP certification, following the Curtis Bay, ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... ISOT ) ("IsoTis"), an orthobiologics company, today announced that,it ... US Food and Drug,Administration ("FDA"), clearing the Accell Family ... medical devices. The Accell Family of Products includes ... well as a new Accell product that is not,currently ...
... CEL-SCI Corporation,(Amex: CVM ), will present ... South Carolina. On August 20, 2007 at ... give a 25-minute presentation regarding CEL-SCI,s late stage,cancer ... a question,and answer session following the presentation and ...
... and Increased Space, Poised for Market Launch, KIRKLAND, ... developing innovative devices for the treatment of arterial,disease, today ... Joseph W.,Rafferty, and has started building its sales team ... PV(TM) Atherectomy System. Recently Pathway moved from its ...
Cached Biology Technology:IsoTis Receives FDA Clearance for Accell Family of Products 2IsoTis Receives FDA Clearance for Accell Family of Products 3IsoTis Receives FDA Clearance for Accell Family of Products 4CEL-SCI to Present at the Noble Financial Conference 2Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth 2
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... orchestrated by a spectrum of signals from hormones within ... cytokinins originate in the roots of plants, and their ... leaves stimulates plant development. Though these phytohormones have been ... their transportation within plants was previously poorly understood. ...
... PA, February 20, 2014 Schizophrenia has long been known ... of the population. Researchers have been following two paths in ... they studied common gene variants that, individually, only increase the ... likelihood of developing schizophrenia from a 10 out of a ...
... fruits and vegetables are associated with higher Body Mass ... households, according to American University researchers in the journal ... significant, association between the prices of fruit and vegetables ... lead author and assistant professor of public administration and ...
Cached Biology News:Roots to shoots: Hormone transport in plants deciphered 2Gathering the clues to rare gene variants contributing to schizophrenia 2High cost of fruits, vegetables linked to higher body fat in young children 2
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
The Protein Kinase Factsbooks (2 Volume Set)...
... Edited by John M. Walker (1996) ... successful analytical techniques for studying proteins ... protocol contains detailed, step-by-step instruction, timesaving ... and comprehensive lists of reagents and ...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Biology Products: